Industry: Biotechnology & Medical Research | LSE
LungLife AI Inc. is Shariah compliant. The company’s financials pass three standards and fail in two.
|Market cap: 50 M||Rev. Growth: 104.91%|
|Debt/36 mo MC||1.26%||✓|
|Cash/36 mo MC||22.79%||✓|
|AR/36 mo MC||%|
|Debt/24 mo MC||1.26%||✓|
|Cash/24 mo MC||22.79%||✓|
|AR/24 mo MC||%|
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Analysts’ Price Targets
Total Analysts: 1
LungLife AI Inc. is a United States-based cancer diagnostics company. The Company is focused on cancer treatment and management through the artificial intelligence (AI) enabled molecular analysis of cancer biomarkers in blood. It is focused on lung cancer from simple blood draw diagnostic solutions. Its technologies include LiquidBiopsy. LiquidBiopsy uses a blood draw, rather than a tissue biopsy, to discover the genomic mutations present or absent within an individual that may be associated with lung cancer. The Company’s LungLB test is positioned to bring certainty into early stage diagnosis confirming for clinicians whether to refer onto biopsy where the low-dose computed tomography (LDCT) scan reveals suspicious nodules.
We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.
To understand how the screening is done, please read the Shariah Screening Methodology page.